SCHEMBL20564478

SCHEMBL20564478

CC(C)c1c(O)nc(-n2ccnc2)nc1-c1cnn(CC(=O)O)c1

nearest known ligand 0.37

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KDM5B Q9UGL1 12/20 0.37
SYK P43405 1/20 0.36
CD38 P28907 2/20 0.34
NPC1 O15118 1/20 0.34
TSHR P16473 1/20 0.34
HSD17B10 Q99714 1/20 0.34
S1PR1 P21453 1/20 0.34
JAK2 O60674 1/20 0.33
JAK1 P23458 1/20 0.33
TYK2 P29597 1/20 0.33
JAK3 P52333 1/20 0.33
MEN1 O00255 1/20 0.33
USP2 O75604 1/20 0.33
LMNA P02545 1/20 0.33
KMT2A Q03164 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
KDM5A P29375 2/20 0.33
KDM5C P41229 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20565455 0.91 KDM5B (0.36) KDM5BCD38JAK2JAK1TYK2
SCHEMBL20957912 0.90 CCNC (0.41) KDM5BCD38NPC1TSHRHSD17B10
SCHEMBL20958016 0.88 KDM5B (0.47) KDM5BCD38NPC1TSHRHSD17B10
SCHEMBL20957919 0.87 KDM5B (0.43) KDM5BCD38NPC1TSHRHSD17B10
SCHEMBL20958010 0.87 KDM5B (0.37) KDM5BCD38JAK2JAK1TYK2
SCHEMBL20957960 0.86 KDM5B (0.44) KDM5BNPC1TSHRHSD17B10JAK2
SCHEMBL20957958 0.86 KDM5B (0.34) KDM5BCD38NPC1TSHRHSD17B10
SCHEMBL20957957 0.85 KDM5B (0.45) KDM5BSYKCD38JAK2JAK1
SCHEMBL20958001 0.85 KDM5B (0.49) KDM5BNPC1TSHRHSD17B10MEN1
SCHEMBL20958031 0.84 KDM5B (0.46) KDM5BSYKCD38JAK2JAK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190135793-A1 HETEROCYCLIC INHIBITORS OF KDM5 FOR THE TREATMENT OF DISEASE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2019-05-09 US disclosed
US-20190135793-A1 HETEROCYCLIC INHIBITORS OF KDM5 FOR THE TREATMENT OF DISEASE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2019-05-09 US disclosed
WO-2018213777-A1 HETEROCYCLIC INHIBITORS OF KDM5 FOR THE TREATMENT OF DISEASE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2018-11-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190135793-A1 HETEROCYCLIC INHIBITORS OF KDM5 FOR THE TREATMENT OF DISEASE KDM5A, KDM5B, KDM5C KDM5B 2/4885SYK 2320/4885CD38 791/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.